Ultiflox

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ultiflox

The following section defines the core identity and pharmacological classification of the medicinal agent containing Fluoxetine. This is a synthetic, prescription-only medication, and the details provided here strictly exclude all information regarding dosages, specific conditions it treats, usage instructions, or safety warnings.


Property Description
Active ingredient Fluoxetine (as hydrochloride salt)
Form Capsule, tablet, oral solution
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
Common use Modulates mood and emotional stability
Origin Synthetic compound

What Type of Medicine is Ultiflox and What is its Role?

Ultiflox is a synthetic psychotropic agent classified as a Selective Serotonin Reuptake Inhibitor (SSRI) within the broader antidepressant class. The medicine is designed to support the regulation of mood and emotional stability by selectively targeting and influencing the brain's chemical signaling pathways. The primary action involves delaying the reabsorption, or "reuptake," of serotonin by nerve cells, which in turn leaves more of this key chemical messenger available to regulate mood and related functions. This mechanism is clinically recognized for its role in addressing imbalances that contribute to persistent low mood and emotional distress. As an SSRI, it operates by subtly modulating the activity of monoamine neurotransmitters, establishing it as a well-supported foundational tool for promoting psychological balance.

Fluoxetine Composition and Available Forms

The therapeutic identity of Ultiflox is founded upon its single active ingredient, Fluoxetine, which is a synthetic compound typically incorporated as the hydrochloride salt. This composition ensures that the product's entire pharmacological activity is derived from the established action of Fluoxetine on the presynaptic serotonin transporter. Ultiflox is prepared for administration via the oral route, being commonly supplied as a solid oral dosage form, such as a capsule or tablet, and is also available as a liquid oral solution. The availability of the oral solution, often utilized for pediatric patients or adults requiring finer dose adjustments, offers a distinct presentation flexibility compared to formulations limited to solid dosage forms. This approach ensures systemic absorption through the digestive tract, allowing the medicine to reach the central nervous system to execute its intended mood-stabilizing action.

What side effects are possible with Ultiflox?

Possible Side Effects and Safety Information

The safety profile of Ultiflox (Fluoxetine) is defined by officially documented adverse reactions, categorized by incidence and the body system affected, as presented in government regulatory documents.

Frequency-Classified Adverse Reactions

The prescribing information classifies several adverse reactions as Most Common (mathbfge 5% and at least twice the rate of placebo). These often involve the Nervous System (e.g., insomnia, somnolence, tremor, anxiety), Gastrointestinal System (e.g., nausea, diarrhea, dry mouth), and general systemic effects (e.g., asthenia, sweating, yawn). Other common effects include decreased libido and abnormal ejaculation.


Serious and Contextual Safety Constraints

Official labeling highlights several serious adverse reactions, including the risk of Suicidal Thoughts and Behaviors, particularly in young adults and adolescents. Other clinically significant concerns are Serotonin Syndrome, which may be heightened during treatment initiation and dose increases, and QT Prolongation, a serious cardiac rhythm abnormality, requiring caution.

Adverse reactions are also grouped by System-Organ-Class, covering Psychiatric, Nervous System, Gastrointestinal, and Metabolic disorders, among others. Hyponatremia (low sodium levels) and Abnormal Bleeding are also documented safety concerns.


Population-Specific Safety Notes

The regulatory profile addresses specific patient populations. The risk of suicidal thoughts and behaviors is explicitly noted in pediatric patients. For patients with hepatic impairment, a lower or less frequent dosage is advised due to the prolonged half-life of the medication and its active metabolite. The risk of Hyponatremia is also considered greater in older adults.

Overdose and Emergency Response

Ultiflox Overdose and When to Seek Help

Overdose with Ultiflox (Fluoxetine) is documented in official prescribing information as presenting with a specific profile of clinical manifestations. These signs include central nervous system effects such as drowsiness, tremor, agitation, and confusion. Physical signs may involve tachycardia (fast heart rate), nausea, and vomiting.

A primary concern documented by regulatory bodies is the potential for severe, life-threatening outcomes. These complications include seizures and severe serotonergic excess, formally termed Serotonin Syndrome. Furthermore, serious cardiac conduction abnormalities such as QT prolongation and ventricular arrhythmia have been reported. Fatality is a documented outcome, particularly when Ultiflox is taken alongside other substances.

In all suspected cases of overdose, official guidance requires the user to seek immediate medical attention. Emergency services must be contacted immediately if symptoms involve a severe compromise, such as collapse, coma (inability to be awakened), or trouble breathing.

Management is strictly supportive, as no specific antidote is known. Official procedures involve establishing an airway, ensuring ventilation, and administering general symptomatic and supportive measures. Due to the long elimination half-life of the medication and its active metabolite, cardiac and vital signs monitoring and prolonged observation in a hospital setting are recommended in regulatory documentation.

Therapeutic Uses of Ultiflox

Ultiflox (Fluoxetine) is commonly used across conditions presenting with episodic or fluctuating manifestations such as Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, and Bulimia Nervosa. The medication is used across domains where additional symptomatic support is needed. It is relevant in contexts involving heightened systemic burden, including complex presentations like Treatment-Resistant Depression or depressive episodes associated with Bipolar I Disorder.

The medication is generally applied in situations involving certain distressing symptoms, including persistent low mood, surges of fear, and disruptive behavioral cycles. It is also relevant for easing symptoms associated with the cyclical affective and somatic manifestations of Premenstrual Dysphoric Disorder (PMDD). This supportive symptom management may help patients cope more steadily with symptom fluctuations and provides supportive relief when symptoms interfere with routine activities.

“The medication is relevant when supportive symptom management is appropriate and contributes to easing the overall symptom load.”


Quick Fact: Relief for Mood and Behavioral Symptoms Ultiflox is applied in clinical settings that involve acute or unstable symptom patterns, contributing to improved comfort during periods of heightened symptoms.

Eligibility and Restrictions for Use

Who Can and Cannot Use Ultiflox? (Official Regulatory Status)

This section describes the official, label-based eligibility requirements for Ultiflox (Fluoxetine), as defined by government regulatory authorities.

Absolute Contraindications (Must Not Use)

Ultiflox is strictly prohibited for patients with a known hypersensitivity to the medication or any of its components. It is also contraindicated for use with certain medications due to serious safety risks:

  • Monoamine Oxidase Inhibitors (MAOIs) intended for psychiatric disorders (requires a mandated 14-day washout period before starting Ultiflox, and a 5-week washout period after stopping Ultiflox).
  • Pimozide or Thioridazine.

Age-Specific Eligibility

Ultiflox is approved for Adults across its labeled uses. For Children and Adolescents, eligibility depends on the condition:

Condition Minimum Approved Age (as per regulatory label)
Major Depressive Disorder (MDD) 8 years and older
Obsessive-Compulsive Disorder (OCD) 7 years and older

Safety and effectiveness for other conditions, such as Bulimia Nervosa or Panic Disorder, have not been established in the pediatric population.

Conditional Use and Restricted Populations

  • Hepatic Impairment: Patients with liver cirrhosis require caution and typically need a lower or less frequent dosage due to reduced clearance.
  • Vulnerable Populations: Caution is required for elderly patients and those with risk factors for QT prolongation (a heart rhythm concern), history of seizures, or untreated anatomically narrow angles.
  • Pregnancy and Lactation: Ultiflox should be used during pregnancy only if the potential benefit justifies the potential risks to the fetus. Breastfeeding is not recommended as the active ingredient is excreted in human milk.

What should I know about interactions with other medicines?

The use of Ultiflox in combination with certain other medicines, supplements, or products may result in documented interactions, requiring management or separation.

Chelation Agents and Supplements

Absorption of Ultiflox is significantly decreased when taken concurrently with multivalent cation-containing products. This interaction, known as chelation, is documented with products such as antacids containing aluminum or magnesium, sucralfate, and supplements containing calcium, iron, or zinc. To mitigate this decrease in absorption, official product labeling requires a time separation between administration, advising that these agents not be taken within four hours of Ultiflox Suspension. Other antibiotics should also be reported.

Drug-Specific and Vaccine Interactions

Official documents note that concurrent use of Ultiflox with Atorvastatin may increase the risk of nerve damage, specifically symptoms such as numbness or tingling. Caution is also advised when Ultiflox is used with oral blood glucose-lowering agents, as this combination necessitates careful monitoring of blood sugar levels. The live Cholera Vaccine is documented to have an interaction with Ultiflox, requiring a mandatory 14-day waiting period after completing Ultiflox Suspension before the vaccine can be administered due to potential interference with the vaccine's effect.

Mechanism of Action

Ultiflox, a fluoroquinolone class antimicrobial, exerts its bactericidal effect by targeting Type II topoisomerases within the susceptible microbial cell. The primary molecular targets are the bacterial enzymes DNA gyrase and topoisomerase IV. Ultiflox functions as an inhibitor by binding to and stabilizing the cleaved enzyme-DNA complexes.

In Gram-negative bacteria, the agent preferentially inhibits DNA gyrase, which is essential for introducing negative supercoils required for replication, transcription, and repair. In Gram-positive bacteria, the agent more significantly targets topoisomerase IV, which mediates the segregation of interlinked daughter chromosomes following DNA replication.

This interaction promotes double-strand DNA breakage and prevents the relegation of DNA strands. The resulting extensive intracellular DNA damage initiates the SOS response and leads to an accumulation of cytotoxic Reactive Oxygen Species (ROS), triggering the terminal cascade of cellular death in the bacterial population.

Dosage and Administration Information

Ultiflox (ciprofloxacin) is an antibiotic and should be used precisely as directed by your healthcare provider to ensure proper eradication of the bacterial infection and to help prevent the development of drug-resistant bacteria.

General Administration

  • Do not skip doses or discontinue the medication prematurely, even if symptoms begin to improve. The full prescribed course must be completed.
  • Take doses at the same time each day to maintain a constant level of the medicine in your system.

Dosage Forms and Specific Instructions

Ultiflox may be available as oral tablets, extended-release tablets, or an oral suspension. Follow the specific instructions for your formulation:

Formulation Instruction for Use
Oral Tablet Swallow the tablet whole with a glass of water. Do not crush, split, or chew unless the tablet is scored and your doctor instructs you to break it.
Extended-Release Tablet Swallow the tablet whole. Do not split, crush, or chew.
Oral Suspension Shake the bottle well for at least 15 seconds before each use. Measure the dose only with the measuring device provided by the pharmacy, not a household spoon.

Important Interactions and Diet

  • Food and Drink: You may take Ultiflox with or without food. However, do not take the medication at the same time as dairy products (like milk or yogurt) or calcium-fortified juices, as these can significantly reduce the medicine's absorption. It is generally acceptable to consume these items as part of a larger meal, but avoid taking them alone with the dose.
  • Other Medications: Certain medications, including antacids, multivitamins, and iron supplements, must be taken at least two hours before or six hours after Ultiflox to prevent interactions that reduce effectiveness. Always inform your doctor or pharmacist of all other medications you are taking.

Recent Clinical Evidence

Ultiflox: Recent Clinical Evidence

Evidence for Use in Major Depressive Disorder (MDD)

Research for Ultiflox in MDD consists of Randomized Controlled Trials (RCTs) and Systematic Reviews exploring how depressive symptoms change over time. Studies in Adults reported measurements of change during acute phases (8 to 12 weeks), and continuation research tracked whether symptomatic patterns persisted or if recurrence was observed. For Pediatric patients, studies examined short-term changes; however, subgroup analyses indicate variability in findings and evidence quality differs across studies. Results apply only to the populations studied.


Evidence for Use in OCD, Panic Disorder, and Related Conditions

For Obsessive-Compulsive Disorder (OCD) and Panic Disorder, the evidence base relies on RCTs and Meta-analyses exploring short-term symptom changes in conditions with fluctuating episodes. For OCD, studies examined outcomes related to the intensity of obsessions and compulsions in adults and youth. This evidence structure is consistent with the medicine's designation as a first-line pharmacological option in certain clinical guidelines.

Ultiflox was also studied for conditions such as Bulimia Nervosa and Premenstrual Dysphoric Disorder (PMDD). Trials for Bulimia focused on measuring reductions in binge-eating and compensatory behaviors, while PMDD studies examined episodic changes in mood and body symptoms.


Evidence in Complex Situations and Research Gaps

Research examined Ultiflox in specialized contexts, including Treatment-Resistant Depression (TRD) and its use in combination with another agent (olanzapine) for Depressive Episodes associated with Bipolar I Disorder. This evidence describes group patterns related to symptomatic change in adults under complex regimens.

The evidence base is primarily built on acute treatment phases (8–12 weeks). While continuation studies provide insight into longer-term patterns, follow-up durations were restricted, meaning data for long-term outcomes remain incomplete. Research gaps also include a lack of formal evaluation for the combination regimen in patients under 18 and limited exploration of doses higher than 60 mg per day for some indications.

Key Studies & References

  1. Fluoxetine - StatPearls (Summary of FDA-approved indications including MDD, OCD, Panic Disorder, Bulimia, TRD, and Bipolar I adjunct)

Frequently Asked Questions (FAQ)

Common questions about Ultiflox (FAQ)

Q: What happens if I miss a dose of Ultiflox?

Official administration rules emphasize that doses should not be skipped, and the full prescribed course must be completed. If a dose is missed, regulatory guidance directs individuals to seek specific instructions from their healthcare provider or pharmacist. This is important because the proper action for a missed dose may depend on the formulation and the timing of the next scheduled dose.

Q: Can Ultiflox be crushed or split?

The official product information specifies that tablets, especially extended-release formulations, must typically be swallowed whole with a glass of water. They should generally not be split, crushed, or chewed. Official documentation notes that scored tablets may be broken only if explicitly directed by a healthcare professional.

Q: What if I have kidney or liver issues? Can I still use Ultiflox?

Official documents address the use of this medicine in patients with hepatic impairment (liver issues). Due to the prolonged time the drug stays in the body, official documents state that a lower or less frequent dosage may be considered for individuals with liver cirrhosis. The official labeling does not typically provide specific dosing instructions for general renal impairment (kidney issues).

Q: What is the purpose of the black box warning mentioned in the official documents for Ultiflox?

The most serious safety notice, known as a Boxed Warning, highlights the risk of suicidal thoughts and behaviors (suicidality). This increased risk has been observed in short-term studies involving children, adolescents, and young adults (under 24 years of age) taking antidepressant medications. This is a standard regulatory measure used to call attention to important safety information.

Q: Is Ultiflox ever prescribed to children?

Yes, according to official regulatory labels, Ultiflox is approved for use in certain pediatric populations. It is indicated for Major Depressive Disorder (MDD) in patients 8 years and older and for Obsessive-Compulsive Disorder (OCD) in patients 7 years and older. Safety and effectiveness for other conditions are generally not established in children and adolescents.

Q: How quickly is Ultiflox expected to start working?

The time it takes for Ultiflox to reach its full therapeutic effect is generally gradual. Although peak concentrations are reached within hours of a single dose, the long half-lives of the drug and its active metabolite mean that the desired steady-state concentrations in the body are typically not reached until 4 to 5 weeks of consistent chronic dosing.

Q: What is the typical duration of effect for a dose of Ultiflox?

Ultiflox is noted in official documents for its long duration of action. The drug has an elimination half-life of approximately 4 to 6 days during chronic use, and its active metabolite, norfluoxetine, remains in the body even longer, with a half-life of up to 4 to 16 days. Due to the long half-lives, the drug's components are known to persist in the body for an extended period following discontinuation.

Q: Does Ultiflox interact with common pain relievers like ibuprofen or acetaminophen?

Official documentation notes a potential increased risk of abnormal bleeding when Ultiflox is co-administered with nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. This is a recognized safety concern. However, regulatory drug labels do not typically note a specific safety interaction with acetaminophen.

Q: Is it safe to drink coffee while taking Ultiflox?

Regulatory drug labels do not generally prohibit the consumption of coffee or caffeine products while taking this medicine. However, because Ultiflox can affect the nervous system, professional guidance suggests that individuals discuss significant dietary changes, including the consumption of high-caffeine products, with a healthcare provider.

Q: Is there a generic version of Ultiflox available?

Yes, the active ingredient contained in Ultiflox is Fluoxetine, which is available as a generic medication. Regulatory bodies review generic versions to ensure they meet the same standards of dosage form, strength, quality, and intended use as the brand-name product.

Q: Is Ultiflox addictive?

Official regulatory bodies do not classify Ultiflox (Fluoxetine) as a controlled substance. Furthermore, the official product documents do not designate the medicine as having a high potential for abuse or addiction.

Q: Does taking Ultiflox make you more sensitive to the sun?

Regulatory adverse reaction lists do not usually include photosensitivity (increased sun sensitivity) as a most common reaction for this medicine. General health precautions, such as avoiding excessive sun exposure, are recommended when taking medication, and any unusual skin reactions should be brought to the attention of a healthcare professional.

Q: What does 'photosensitivity' mean in the context of Ultiflox?

Photosensitivity describes a heightened sensitivity to sunlight or other sources of UV radiation. If a drug causes this effect, sun exposure can result in a more severe sunburn or skin rash than would normally be expected. Although not a common adverse reaction for Ultiflox, it is a general precaution to be aware of.

Q: Are there any long-term side effects associated with Ultiflox?

Official research evidence is built primarily on acute treatment phases, and regulatory documents note that data for very long-term outcomes may be incomplete. However, the long-term safety profiles tracked in continuation studies highlight potential considerations such as sexual side effects and weight changes in some patients.

Q: How does the body get rid of Ultiflox after the treatment is over?

According to pharmacokinetic data in official documents, the medicine is extensively processed in the liver to form its active metabolite. Ultiflox and its metabolite are then eliminated from the body predominantly through the urine.

Q: Is it okay to exercise or lift weights while taking Ultiflox?

Regulatory documents do not contain general restrictions against physical activity or weightlifting while using this medicine. However, because the drug can be associated with central nervous system effects (like dizziness) and musculoskeletal effects (like tremor), awareness of one’s reaction during physical activity is advised.

Q: What is the typical time frame for side effects to appear after starting Ultiflox?

Regulatory warnings state that serious safety concerns, such as Serotonin Syndrome, are more likely to be heightened during the initiation of treatment and dose increases. More common side effects typically manifest within the first few weeks of therapy as the body adjusts to the medication.

Q: Does Ultiflox cause dizziness or difficulty driving?

Official medication guides indicate that Ultiflox may cause somnolence (drowsiness) or impair a patient’s ability to think clearly, make decisions, or react quickly. Regulatory warnings recommend against driving or operating heavy machinery until an individual is certain how the medication affects them.

Q: Can Ultiflox interact with herbal products?

Official regulatory documents advise caution against or note potential risks from combining Ultiflox with certain herbal supplements. For example, co-administration with herbal products that increase serotonin activity, such as St. John's Wort, is noted to increase the risk of Serotonin Syndrome.

Q: Why is the eligibility section so strict about who can use Ultiflox?

The strictness in the eligibility criteria (contraindications) is mandated by regulatory bodies to prevent serious, life-threatening reactions. These include the risk of Serotonin Syndrome when the drug is used with Monoamine Oxidase Inhibitors (MAOIs), or severe cardiac rhythm problems when used with medications like Pimozide or Thioridazine.

Q: Is there a different name for Ultiflox in other countries?

The generic name of the active ingredient is Fluoxetine, and it is marketed under various brand names globally. While the medicine's trade name may change depending on the country, the underlying active ingredient and its function remain consistent.

Q: What does it mean that Ultiflox is 'not indicated' for certain conditions?

When a medication is described as 'not indicated' for a specific condition, it means that regulatory agencies have not formally reviewed and approved the drug's use for that purpose. This usually signifies that the safety and effectiveness of the medicine for that condition have not been established through required clinical trials.

How should Ultiflox be stored and disposed of?

How to Store and Dispose of Ultiflox (Fluoxetine)

Ultiflox must be stored according to official regulatory labeling to ensure product stability.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (CRT), ideally 20 C to 25 C.
Protection Protect from excessive heat and moisture; keep the container tightly closed.
Prohibited The oral solution formulation must not be frozen.
Safety Keep all forms of the medicine out of the sight and reach of children.
Container Store the medication in its original container.

Disposal

Unused or expired Ultiflox must not be discarded in the household trash or wastewater (e.g., flushed down the toilet). Dispose of the medicine strictly in accordance with local regulatory requirements to ensure environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ultiflox found in:

A-Z Index: